항생제 개발의 역사 및 현황
The History of Antimicrobial Drug Development and the Current Situation
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Since development of the first antimicrobial agents in the 1940s, antimicrobial resistance has been an issue. Following the introduction of sulfonamides and penicillin, scientists discovered and developed a wide range of antimicrobials for treatment of bacterial diseases. Many new antimicrobials were discovered by systematic testing of soil microbes and many others were developed by chemical modification of existing agents. Discovery of new classes of antibacterial drugs slowed in the late 1960s. However, the speed with which bacteria develop resistance to antibiotics, in contrast with the slow development of new drugs, has led some experts to warn of a "post-antibiotic era." Judicious use of currently available antibiotics, through efforts such as public campaigns for 'appropriate antibiotic use', may help to conserve their effectiveness. However, even if we improve these practices, development of resistant bacteria will continue to occur, and new and better drugs will be needed. Clearly, a combination of traditional successful methods and modern technology will be needed for discovery and development of new classes of antibacterial drugs. In addition, policies that encourage and facilitate development of new antimicrobial agents are also needed.
Abstract
Since development of the first antimicrobial agents in the 1940s, antimicrobial resistance has been an issue. Following the introduction of sulfonamides and penicillin, scientists discovered and developed a wide range of antimicrobials for treatment of bacterial diseases. Many new antimicrobials were discovered by systematic testing of soil microbes and many others were developed by chemical modification of existing agents. Discovery of new classes of antibacterial drugs slowed in the late 1960s. However, the speed with which bacteria develop resistance to antibiotics, in contrast with the slow development of new drugs, has led some experts to warn of a "post-antibiotic era." Judicious use of currently available antibiotics, through efforts such as public campaigns for 'appropriate antibiotic use', may help to conserve their effectiveness. However, even if we improve these practices, development of resistant bacteria will continue to occur, and new and better drugs will be needed. Clearly, a combination of traditional successful methods and modern technology will be needed for discovery and development of new classes of antibacterial drugs. In addition, policies that encourage and facilitate development of new antimicrobial agents are also needed.
참고문헌 (25)
- Wenzel RP., "The antibiotic pipeline-challenges, costs, and values", N Engl J Med, 351, pp.523~526 (2004)
- Skinner D., "Significance of bacteremia caused by Staphlyococcus aureus", Arch Intern Med, 68, pp.851~875 (1941)
- Alanis AJ., "Resistance to antibiotics : are we in the postantibiotic era?", Arch Med Res, 36, pp.697~705 (2005)
- Falagas ME., "Pandrug-resistant Gram-negative bacteria : the dawn of the post-antibiotic era?", Intern J Antimicrob Agents, 29, pp.630~636 (2007)
- Outterson K., "Will longer antimicrobial patents improve global public health?", Lancet Infect Dis, 7, pp.559~566 (2007)
- Talbot GH., "Bad bugs need drugs : an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America", Clin Infect Dis, 42, pp.657~668 (2006)
- Diekema DJ., "Antimicrobial resistance trends and outbreak frequency in United States hospitals", Clin Infect Dis, 38, pp.78~85 (2004)
- Spellberg B., "Trends in antimicrobial drug development : implications for the future", Clin Infect Dis, 38, pp.1279~1286 (2004)
- Boucher HW., "Bad bugs, no drugs : no ESKAPE! An update from the Infectious Diseases Society of America", Clin Infect Dis, 48, pp.1~12 (2009)
- DiMassa JA., "The price of innovation : new estimates of drug development costs", J Health Econ, 22, pp.151~185 (2003)
- Projan SJ., "Why is big pharma getting out of antibacterial drug discovery?", Curr Opin Microbiol, 6, pp.427~430 (2003)
- Powers JH., "Development of drugs for antimicrobial-resistant pathogens", Curr Opin Infect Dis, 16, pp.547~551 (2003)
- Norrby SR., "Lack of development of new antimicrobial drugs : a potential serious threat to public health", Lancet Infect Dis, 5, pp.115~119 (2005)
- Wenzel RP., "Managing antibiotic resistance", N Engl J Med, 343, pp.1961~1963 (2000)
- Hoel D., "Antibiotics: past, present, and future. Unearthing nature's magic bullets", Postgrad Med, 101, pp.114~122 (1997)
- Lloyd NC., "The composition of Ehrlich's Salvarsan : Resolution of a centuryold debate", Angew Chem Int Ed, 44, pp.941~944 (2005)
- Lesch JE., "Prontosil, In The first miracle drugs: how the sulfa drugs transformed medicine", pp.51~ (2007), Oxford University Press
- Schwentker FF., "The treatment of meningococcic meningitis", JAMA, 108, pp.1407~1408 (1937)
- Powers JH., "Antimicrobial drug development-the past, the present, and the future", Clin Microbiol Infect Dis, 10(Supple 4), pp.23~31 (2004)
- Fleming A., "The antibacterial action of cultures of a Peni cillium, with special reference to their use in the isolation of B. influenzae", Br J Exp Pathol, 10, pp.226~236 (1929)
- Levy SB., "From tragedy the antibiotic era is born, In The Antibiotic Paradox; How the misuse of antibiotics destroys their curative powers, 2nd ed", pp.1~14 (2002), Perseus Publishing
- Lewis K., "Recover the lost art of drug discovery", Nature, 485, pp.439~440 (2012)
- Fernandes P., "Antibacterial discovery and development-the failure of success?", Nature Biotechnol, 24, pp.1497~1503 (2006)
- Clatworthy AE., "Targeting virulence : a new paradigm for antimicrobial therapy", Nature Chemical Biology, 3, pp.541~548 (2007)